Communiqués Decoy Therapeutics Inc.

Actions

DCOY

US79400X5032

Recherche biotechnologique et médicale

Temps Différé Nasdaq Autres places de cotation 22:00:00 10/02/2026			Varia. 5j.	Varia. 1 janv.
0,7481 ^USD	-2,84%		+9,69%	+15,31%

23/01	DECOY THERAPEUTICS INC. : Ladenburg Thalmann maintient sa recommandation à l'achat	ZM
13/01	Decoy Therapeutics conclut un accord mondial pour développer une plateforme de fabrication de conjugués peptidiques accessible à l'échelle internationale	CI

Communiqués

15:01	Decoy Therapeutics Joins Webull Corporate Connect Service Platform	PR
05/02	Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial	PR
04/02	Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement	PR
13/01	Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform	PR
07/01	Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics	AQ
19/12	Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting	AQ
18/12	Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform	AQ
01/12	Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study	AQ
20/11	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol SLRX	AQ
19/11	Salarius Pharmaceuticals : Cites Errors on S&P CapIQ...	PU
19/11	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”	AQ
14/11	Salarius: Q3 Earnings Snapshot	AQ
13/11	Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger	AQ
11/11	Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering	PR
13/10/25	Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements	AQ
09/09/25	Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
14/08/25	Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split	AQ
12/08/25	Salarius: Q2 Earnings Snapshot	AQ
14/07/25	Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard	AQ
09/07/25	Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies	AQ
17/06/25	Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge - Material Gains & More Stocks Inside	AQ
14/05/25	Salarius: Q1 Earnings Snapshot	AQ
16/04/25	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board	AQ
26/03/25	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses	AQ
24/03/25	Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse Idées de trading

Communiqués Decoy Therapeutics Inc.

Actions

DCOY

US79400X5032

Recherche biotechnologique et médicale

Communiqués

Filtres